Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$86.43 USD
-1.58 (-1.80%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $86.49 +0.06 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Edwards Lifesciences (EW) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$92.73 | $105.00 | $72.00 | 5.36% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for Edwards Lifesciences comes to $92.73. The forecasts range from a low of $72.00 to a high of $105.00. The average price target represents an increase of 5.36% from the last closing price of $88.01.
Analyst Price Targets (22)
Broker Rating
Edwards Lifesciences currently has an average brokerage recommendation (ABR) of 2.16 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 2.16 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 48% and 4% of all recommendations. A month ago, Strong Buy made up 48%, while Buy represented 4%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 11 | 10 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 10 | 10 | 10 | 11 | 12 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.16 | 2.16 | 2.16 | 2.24 | 2.32 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/26/2024 | Piper Sandler | Adam C Maeder | Hold | Hold |
4/17/2024 | Truist Securities | Richard Newitter | Strong Buy | Strong Buy |
4/11/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
4/5/2024 | SVB Securities | Michael Kratky | Hold | Hold |
4/4/2024 | Evercore Partners | Vijay Kumar | Hold | Hold |
1/7/2024 | BTIG | Marie Thibault | Not Available | Hold |
10/31/2023 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
10/25/2023 | Not Identified | Not Identified | Hold | Hold |
7/27/2023 | Canaccord Genuity | William J Plovanic | Hold | Hold |
7/19/2023 | Robert W. Baird & Co. | David Rescott | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.16 |
ABR (Last week) | 2.16 |
# of Recs in ABR | 25 |
Average Target Price | $92.73 |
LT Growth Rate | 7.30% |
Industry | Medical - Instruments |
Industry Rank by ABR | 94 of 252 |
Current Quarter EPS Est: | 0.70 |